Added to YB: 2026-04-02
Pitch date: 2026-03-31
290650.KQ [bullish]
L&C BIO Co.,LTD
-0.71%
current return
Author Info
The Consumer Ascent shares fundamental research and channel checks on emerging global consumer brands. Sign up for the newsletter.
Company Info
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products.
Market Cap
KRW 1.7T
Pitch Price
KRW 70.5K
Price Target
96.0K
Dividend
N/A
EV/EBITDA
152.45
P/E
-11.56
EV/Sales
20.33
Sector
Biotechnology
Category
growth
Re2O: The Next Generation Botox - L&C Bio
290650.KQ: L&C Bio's Re2O injectable (processed human ECM) commands 80-170% price premium over incumbent Rejuran ($650K vs $242K-$363K/session) w/ faster adoption (500→2,000+ clinics in <1yr). Production scaling from 30K to 80K units/month starting May '26 (vs H2 guidance), targeting 150K+ by Oct. Korea dominance, Japan live, China trials 2026. Legacy surgical grafts ($100M rev, stable margins) fund expansion. Capacity-constrained 2025 rev $85.5M understates demand; 2027E rev ~$300M w/ Re2O at $200M implies EPS ~$3,000-$3,500. At 30x fwd, PT ~₩96K. Bull case: global platform w/ manufacturing moat. Risks: ramp delays, China NMPA timeline, U.S. FDA path unclear. May production inflection critical catalyst.
Read full article (21 min)